tbuckley/cabot-search huggingface dataset:
Abstract 3774: Investigating the role of CDC25B in inhibition of cellular proliferation
Authors: Caleb C. Lee, James Manfredi
Journal: Cancer Research (2015)

Abstract CDC25B is a dual specificity phosphatase that activates cyclin-dependent kinases to trigger entry into mitosis and is required for re-entry into mitosis after DNA damage. Four isoforms of CDC25B are known to be expressed and some differences in their role in dividing cells versus continuation of the cell cycle after DNA damage have been shown. As an oncogene, CDC25B is upregulated by c-Myc and activated by Aurora-A. In humans, CDC25B is overexpressed in multiple tumor types and increased levels correlate with worsening tumor grade. In a transgenic mouse model, overexpression of CDC25B in the mammary glands led to accelerated mammary epithelial proliferation resulting in hyperplasia and the formation of tumors when exposed to the carcinogen DMBA. In vitro, co-transfection of CDC25B with Ras allows for transformation of MEF’s. Surprisingly, given the establishment of CDC25B as an oncogene, colony formation assays using ectopic expression of CDC25B in transformed cell lines reveal an anti-proliferative effect. Although CDC25B has been shown to cause DNA damage and activates p53, our data show that colony formation is decreased independent of p53 status. Preliminary data reveal a role for Ras inhibition as a cause of this anti-proliferative effect. Co-transfection of CDC25B and activated Ras results in decreased expression of the ectopic Ras protein in several cell lines tested. Furthermore overexpression of CDC25B abrogates the G2 arrest and decreases cell viability after pulse treatment with doxorubicin. Taken together, these data suggest a novel mechanism by which CDC25B may inhibit proliferation by decreasing Ras expression. Citation Format: Caleb C. Lee, James Manfredi. Investigating the role of CDC25B in inhibition of cellular proliferation. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3774. doi:10.1158/1538-7445.AM2015-3774
Effect of EGFR inhibition with cetuximab (CET) on the efficacy of paclitaxel (TAX) in previously treated metastatic (MET) urothelial cancer.
Authors: Y. Wong, S. Litwin, D. J. Vaughn, E. R. Plimack, W. Song, J. W. Lee, M. B. Dabrow, M. Brody, H. Tuttle, G. R. Hudes
Journal: Journal of Clinical Oncology (2011)

4617 Background: The benefit of salvage chemotherapy (chemo) such as weekly TAX is modest in met urothelial ca, with median (med) TTP of ≤3 months and ORR of 10% (95% CI 4-18% (combined results, Vaughn 2002, Joly 2009) High grade urothelial cancer overexpress the epidermal growth factor receptor (EGFR). CET is a monoclonal antibody against EGFR. We conducted a multicenter randomized, noncomparative phase II study to measure the efficacy of CET +/- TAX in patients (pts) with previously treated met urothelial cancer. Methods: Pts with met urothelial cancer who received 1 line of chemo in the perioperative or met setting were enrolled. Pts were randomized to CET 250mg/m2 (after 400 mg/m2 load) +/- TAX 80 mg/m2 weekly. A cycle was 4 weeks (wks). Response (RECIST) was assessed by imaging every 8 wks. We used early progression to assess futility (Litwin Stats Med 2007). Either arm would close if 7 of the initial 15 pts in that arm progressed at the 1st disease evaluation. Either arm would be considered promising if ≥9/28 patients had PFS>16 wks (90.4% power to detect an improvement in Med PFS from 8 to 16 wks with a 7.1% Type 1 error). Results: We enrolled 39 evaluable pts (30 male). Med age was 69 years (range 49-79). All pts received prior platinum based chemo in the perioperative (42.8%) or met setting. CET arm closed after 9 of the 1st 11 pts progressed by 8 wks. CET-TAX arm completed full accrual of 28 pts, of which 22 (78.5%) had visceral disease. 11/28 pts had PFS>16 wks. ORR was 25% (95% CI 11%-45%; 1 CR 6PR). Among responders, med duration of response was 190 days (range 56-557) of which 3 have PRs lasting 183, 176, 56+ days after stopping therapy. Med PFS for the CET-TAX was 16 wks (115 days 95% CI 84-207). Med PFS for pts with visceral disease was 112 days (95%CI 58-207). Med PFS for pts with prior perioperative chemo only was 158 days (95% CI 113-NR). Med OS was 37 wks (259 days; 95% CI 195-347). Treatment related AEs grade ≥3 occurring >2 pts were rash (6), fatigue (5), and low magnesium (3). Conclusions: EGFR inhibition with CET appears to augment the antitumor activity of TAX in pts with previously treated urothelial cancers. The CET-TAX combination merits further study to establish its role in treatment of urothelial cancers.
AUTHORS' REPLY
Authors: J.-H. Lai, S.-J. Kao, C.-Y. Shen
Journal: Thorax (1991)

Although we agree with most of the review, we would disagree with their comments on hypoxaemia.They state that absence ofhypoxaemia in vocal cord dysfunction helps to differentiate this condition from acute asthma.We have seen two cases ourselves' where hypoxaemia is a feature of vocal cord dysfunction.In one case the hypoxaemia (arterial oxygen tension Pao2) 79 mm Hg with 100%
The SPRY domain–containing SOCS box protein SPSB2 targets iNOS for proteasomal degradation
Authors: Zhihe Kuang, Rowena S. Lewis, Joan M. Curtis, Yifan Zhan, Bernadette M. Saunders, Jeffrey J. Babon, Tatiana B. Kolesnik, Andrew Low, Seth L. Masters, Tracy A. Willson, Lukasz Kedzierski, Shenggen Yao
Journal: The Journal of Experimental Medicine (2010)
Highlights
Journal: JAMA Neurology (2018)

Risk of Unnatural Mortality in People With Epilepsy 929In a population-based cohort study using 2 linked primary care data sets from the general populations of England and Wales, Gorton and coauthors estimated the risk of unnatural mortality in more than 50 000 people with epilepsy and 1 million matched individuals without.The risks of death by unintentional injury, intentional and unintentional self-poisoning with medication, and suicide were particularly elevated in people with epilepsy, while opioid and psychotropic medication poisoning were common in people with and without epilepsy.Editorial perspective is provided by Devinsky and coauthors.
Poster Session 3: Adaptive and Innate Immunology; Alcohol: Clinical and Experimental
Journal: Hepatology (2015)

with adequate control of dyslipidemia in both groups.Blood glucose was higher in CNI (p<0.05) but there was no difference in new onset type 2 diabetes mellitus between groups at the end of follow-up.Biopsy proven acute rejection was seen in 2 (6%) patients in the CNI/SRL group and 5 (16%) in the CNI group.A total of 8 (24%) patients died in CNI/SRL group.Main causes of death included hepatocellular carcinoma recurrence (n=3), infections (n=3), cardiovascular events (n=1) and CKD secondary to diabetic nephropathy and recurrence of cirrhosis due to NASH (n=1).In CNI group, 9 (29%) patients died.Causes of death were recurrence of biliary cirrhosis (n=1), secondary sclerosing cholangitis (n=1), CKD secondary to diabetic nephropathy (n=2), chronic graft rejection (n=2) and infections (n=3).Immunosuppression reduction was achieved in 9 (27%) patients receiving SRL without evidence of rejection.CONCLUSION: early conversion to SRL preserves renal function and avoids irreversible kidney damage, with no difference in graft rejection patient survival, and metabolic side effects compared with continued CNIs.
Pain Control and the World Health Organization Analgesic Ladder
Authors: Marcus M. Reidenberg
Journal: JAMA (1996)

<h3>To the Editor.</h3> —Drs Jadad and Browman<sup>1</sup>review literature to evaluate the effectiveness of the World Health Organization (WHO) analgesic ladder approach to treating cancer pain. They state, "Unless there are controlled studies, it would be difficult to know whether the WHO ladder has really improved the management of cancer pain." They ignore the real worldwide issue of "improved" compared to what? This WHO program had as its major goal making opioid analgesics available to everyone in the world suffering from pain from advanced cancer. The ladder approach was to facilitate the acceptance of opioid use in these patients since historically opioid use was condemned by medical authorities "if it [could] possibly be avoided,"<sup>2</sup>and surveys have found inadequate use of opioids to treat cancer pain (references cited in reference 1). One should assess the success of the ladder concept by learning what fraction of dying cancer patients
Sporotrichosis in Western Pennsylvania. Report of two cases
Authors: J. B. Hanrahan
Journal: JAMA (1966)

SPOROTRICHOSIS has been reported infrequently from Western Pennsylvania.<sup>1</sup>While the paucity of reports may not reflect the true occurrence of the disease in this area, it is unlikely that there have been any large outbreaks such as have occurred recently in Vermont and Florida.<sup>2,3</sup>During the past ten years, two cases of cutaneous sporotrichosis have been seen at the Western Pennsylvania Hospital. These cases are being reported because they occurred in nonhorticultural workers, and because one case represents an unusual complication of cutaneous sporotrichosis. <h3>Report of Cases</h3><h3>Case 1.—</h3> This 63-year-old veterinarian, who resided and practiced in a Pittsburgh suburb, was first seen by his physician on July 12, 1957, with an ulcer on his right forearm and lymphangitis of his right upper arm occurring after a scratch from an animal under his care. The lesion was cultured and excised. Histologic examination revealed a granulomatous reaction and cultures
Impotence
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human Health Effects of Dichloromethane: Key Findings and Scientific Issues
Authors: Paul M. Schlosser, Ambuja S. Bale, Catherine F. Gibbons, Amina Wilkins, Glinda S. Cooper
Journal: Environmental Health Perspectives (2014)

Background: The U.S. EPA’s Integrated Risk Information System (IRIS) completed an updated toxicological review of dichloromethane in November 2011.Objectives: In this commentary we summarize key results and issues of this review, including exposure sources, identification of potential health effects, and updated physiologically based pharmacokinetic (PBPK) modeling.Methods: We performed a comprehensive review of primary research studies and evaluation of PBPK models.Discussion: Hepatotoxicity was observed in oral and inhalation exposure studies in several studies in animals; neurological effects were also identified as a potential area of concern. Dichloromethane was classified as likely to be carcinogenic in humans based primarily on evidence of carcinogenicity at two sites (liver and lung) in male and female B6C3F1 mice (inhalation exposure) and at one site (liver) in male B6C3F1 mice (drinking-water exposure). Recent epidemiologic studies of dichloromethane (seven studies of hematopoietic cancers published since 2000) provide additional data raising concerns about associations with non-Hodgkin lymphoma and multiple myeloma. Although there are gaps in the database for dichloromethane genotoxicity (i.e., DNA adduct formation and gene mutations in target tissues in vivo), the positive DNA damage assays correlated with tissue and/or species availability of functional glutathione S-transferase (GST) metabolic activity, the key activation pathway for dichloromethane-induced cancer. Innovations in the IRIS assessment include estimation of cancer risk specifically for a presumed sensitive genotype (GST-theta-1+/+), and PBPK modeling accounting for human physiological distributions based on the expected distribution for all individuals 6 months to 80 years of age.Conclusion: The 2011 IRIS assessment of dichloromethane provides insights into the toxicity of a commonly used solvent.Citation: Schlosser PM, Bale AS, Gibbons CF, Wilkins A, Cooper GS. 2015. Human health effects of dichloromethane: key findings and scientific issues. Environ Health Perspect 123:114–119; http://dx.doi.org/10.1289/ehp.1308030
ECG's Transmitted by Long-Distance Telephone Provide Consultation for Midwest Physicians
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LAW &amp;amp; MEDICINE
Authors: Edwin J. Holman
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Occupational Medicine
Authors: Arthur L. Frank
Journal: JAMA (1990)

The field of occupational medicine has received much attention at the national level in recent months as a committee of the National Academy of Sciences has evaluated the status of the field and its relationship to primary care. There has also been much introspection among occupational health specialists as they assess the role of their specialty in primary care. What is becoming clear is that while there is a continuing need for certified specialists in occupational medicine, primary care providers such as internists, family practitioners, and general practitioners are the usual source of occupational health care for most workers. This implies that these fields, particularly general internal medicine and family practice, will require more training in occupational medicine during residency. In recognition of this reality, this year the National Institute for Occupational Safety and Health has awarded some initial grants to further integrate occupational medicine training into the curricula of
Human Physiology
Authors: Robert L. Vick
Journal: JAMA (1990)

This is the second edition of an English version of a long-established German textbook. The translation is a triumph—there is no awkward phrasing or any other indication that this book was not originally written in English. The book is relatively brief, although all of the traditional topics are covered. Unfortunately, some of the sections, most notably that on endocrinology, are too brief. The text is up-to-date in most respects, although there are some surprising exceptions. For example, the subdivision of adrenergic receptors (eg, α<sub>1</sub>, α<sub>2</sub>, β<sub>1</sub>, and β<sub>2</sub>) is given only the briefest mention, and the description of the cardiac pacemaker mechanism is not current. Some areas simply are not covered well. The cardiac atrioventricular junction, for example, is not characterized at all. As seems to be usual with textbooks that have gone through several editions, new material is added, but old material is not always
Activated innate immune system in irritable bowel syndrome?
Authors: J Langhorst, A Wieder, A Michalsen, F Musial, G J Dobos, A Rueffer
Journal: Gut (2007)

allowed to undertake all endoscopic procedures in the field of conventional endoscopy.A recent editorial from Dewitt 1 asks, ''Is there anything now we can't do?'' with double balloon enteroscopy.We would ask, ''Is there anything now we can do''?We encountered the case in our early experience of double balloon enteroscopy, and only a diagnostic endoscope was available in Taiwan.Because of our limited experience in the use of double balloon enteroscopy and the lack of suitable haemostasis equipment, a discussion with the patient was held and it was determined that he preferred the option of surgical resection of the polyp.At present, we are capable of diagnosing various small intestinal diseases with the use of double balloon enteroscopy.However, we still need more experience to improve our technique for treating the lesions found and managing the associated complications.More studies are required to show the effectiveness and safety of therapeutic double balloon enteroscopy compared with traditional methods.
Update: Transmission of HIV Infection During Invasive Dental Procedures—Florida
Journal: JAMA (1991)

Previous reports from an epidemiologic investigation in Florida strongly suggested that three patients (patients A, B, and C) became infected with human immunodeficiency virus (HIV) while receiving dental care from a dentist with acquired immunodeficiency syndrome (AIDS) (1,2). This report describes findings that suggest HIV was transmitted to two additional patients (patients E and G). These two patients had no other confirmed exposures to HIV, had invasive procedures performed by the dentist, and are infected with HIV strains that are closely related genetically to the strains from the three previously reported patients and from the dentist (Table 1). In addition, this report describes the epidemiologic and laboratory investigation of another HIV-infected patient of the dentist (patient F).
Effects of Physical Forces on the Reproductive Cycle
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Major
Authors: GREGORY FRIESS
Journal: Annals of Internal Medicine (1984)

Ad Libitum1 September 1984The MajorGREGORY FRIESS, D.O.GREGORY FRIESS, D.O.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-3-407_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAs he entered the roomA blend of bugles could be heard,Or should have been,To the ColorsFor here was a cavalryman.Standing straight and slowly movingHe declined my chairAnd uncomfortably I took his history, also standing.Only months later as we stoodDid he casually comment that the bone painNever let him sit,Never.The bony metastases of prostate remained untreatedBy his command(How could a man who'd heard the bugle charge consider castration, estrogens or drugs?) After he'd diedI could still hear the bugles blendNot taps, butTo the Colors.... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Fort Sam Houston, Texas PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1984Volume 101, Issue 3Page: 407-407KeywordsBoneDrugsEstrogens ePublished: 1 December 2008 Issue Published: 1 September 1984 PDF downloadLoading ...
A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Authors: Aziz Nazha, Hagop M. Kantarjian, Gautam Borthakur, Guillermo Garcia-Manero, Tapan M. Kadia, Stefan Faderl, Zeev Estrov, Elias Jabbour, Alfonso Quintas-Cardama, Farhad Ravandi, Jorge E. Cortes
Journal: Blood (2012)
Those who 'eat and run' may lead healthier lives
Authors: M. Korcok
Journal: JAMA (1983)

Weight control is often thought of as a trial of self-denial. However, a two-year study of middle-aged runners shows that it is not only possible to eat more while weighing less, but it also seems healthier to eat more—as long as you keep on exercising. According to Peter D. Wood, DSc, professor of medicine (research) and deputy director of the Stanford (Calif) University Heart Disease Prevention Program, it is known that very active persons eat a greater amount of food than their more sedentary cohorts. In addition, it has been shown that many active persons decrease their proportion of body fat and improve their lipoprotein status. Low-density lipoprotein (LDL) cholesterol and very-low-density lipoprotein (VLDL) cholesterol levels drop sharply, and high-density lipoprotein (HDL) cholesterol levels increase markedly. The new data again confirm these findings, but also show something else: The active persons studied ate different foods—more complex carbohydrates, fiber, vitamins, and